DOCSLIB.ORG

2020.10.15.20213553V1.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020.10.15.20213553V1.Full.Pdf medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 1 Effect of human umbilical cord-derived mesenchymal stem cells on lung 2 damage in severe COVID-19 patients: a randomised, double-blind, 3 placebo controlled phase 2 trial 4 Lei Shi1,2*, Hai Huang3,4*, Xuechun Lu2,5*, Xiaoyan Yan6*, Xiaojing Jiang7, Ruonan Xu1, 5 Siyu Wang1, Chao Zhang1,2, Xin Yuan1,2, Zhe Xu1,2, Lei Huang1,2, Jun-Liang Fu1,2, 6 Yuanyuan Li1, Yu Zhang8,9, Weiqi Yao9,10, Tianyi Liu2,11, Jinwen Song1,2, Liangliang 7 Sun4,12, Fan Yang13, Xin Zhang2,14, Bo Zhang7, Ming Shi1, Fanping Meng1, Yanning Song1, 8 Yongpei Yu6, Jiqiu Wen2, Qi Li2, Qing Mao2, Markus Maeurer16,17, Alimuddin Zumla18, 9 Chen Yao6#, Wei-Fen Xie4,15#, Fu-Sheng Wang1,2# 10 11 1. Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General 12 Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. 13 2. Wuhan Huoshenshan Hospital, Wuhan, China. 14 3. Department of Respiratory, Changzheng Hospital, Second Military Medical University, 15 Shanghai, China. 16 4. Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan, 17 China. 18 5. Department of Hematology, Second Medical Center of Chinese PLA General Hospital, 19 Beijing, China. 20 6. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, 21 China. 22 7. Department of Infectious Disease, General Hospital of Central Theater Command, 23 Wuhan, China. Page 1 of 28 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 24 8. VCANBIO Cell & Gene Engineering Corp., Ltd. Tianjin, China. 25 9. National Industrial Base for Stem Cell Engineering Products, Tianjin, China. 26 10. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong 27 University of Science and Technology, Wuhan, China. 28 11. Key Laboratory of Cancer Center, Fifth Medical Center of Chinese PLA General 29 Hospital, Beijing, China. 30 12. Department of Endocrinology and Metabolism, Changzheng Hospital, Second Military 31 Medical University, Shanghai, China. 32 13. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 33 University of Science and Technology, Wuhan, China. 34 14. Nursing Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 35 China. 36 15. Department of Gastroenterology, Changzheng Hospital, Second Military Medical 37 University, Shanghai, China. 38 16. Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal. 39 17. I Med Clinic, University of Mainz, Mainz, Germany. 40 18. Center for Clinical Microbiology, Division of Infection and Immunity, University 41 College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK 42 * Drs. Lei Shi, Hai Huang, Xuechun Lu and Xiaoyan Yan contributed equally to this 43 article. 44 Correspondence to: 45 # Prof. Fu-Sheng Wang, Department of Infectious Diseases, Fifth Medical Center of 46 Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Page 2 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 47 No.100 Western 4th Ring Road, Beijing 100039, China. [email protected] 48 # Prof. Wei-Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second 49 Military Medical University, 415 Fengyang Road, Shanghai, 200003, China. 50 [email protected] 51 # Prof. Chen Yao, Peking University Clinical Research Institute, Peking University First 52 Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China 53 [email protected] Page 3 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 54 Abstract 55 Objective 56 To assess the safety and efficacy of human umbilical cord-derived MSCs (UC-MSCs) for 57 severe COVID-19 patients with lung damage. 58 Design, 59 Multicentre, randomised, double-blind, placebo-controlled trial. 60 Setting 61 Two hospitals in Wuhan, China, 5 March 2020 to 28 March 2020. 62 Participants 63 101 severe COVID-19 patients with lung damage aged between 18–74 years. 64 Intervention 65 Patients were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4 × 107 cells 66 per infusion) or placebo on days 0, 3, and 6. 67 Main outcome measures 68 The primary endpoints were safety and an altered proportion of whole lung lesion size 69 from baseline to day 28, measured by chest computed tomography. Secondary outcomes 70 were reduction of consolidation lesion sizeand lung function improvement (6-minute walk 71 test, maximum vital capacity, diffusing capacity). Primary analysis was done in the 72 modified intention-to-treat (mITT) population and safety analysis was done in all patients 73 who started their assigned treatment. 74 Results 75 100 patients were finally recruited to receive either UC-MSCs (n = 65) or placebo (n = 35). 76 The patients receiving UC-MSCs exhibited a trend of numerical improvement in whole 77 lung lesion size from baseline to day 28 compared with the placebo cases (the median 78 difference was -13.31%, 95%CI -29.14%, 2.13%, P=0.080). UC-MSCs administration Page 4 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 79 significantly reduced the proportions of consolidation lesion size from baseline to day 28 80 compared with the placebo (median difference: -15.45%, 95% CI -30.82%, -0.39%, 81 P=0.043). The 6-minute walk test showed an increased distance in patients treated with 82 UC-MSCs (difference: 27.00 m, 95% CI 0.00, 57.00, P=0.057). The incidence of adverse 83 events was similar, and no serious adverse events were observed in the two groups. 84 Conclusions 85 UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 86 patients with lung damage. A phase 3 trial is required to evaluate effects on reducing 87 mortality and preventing long-term pulmonary disability. 88 Trial registration 89 ClinicalTrials.gov Identifier: NCT04288102 Page 5 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 90 Key Points 91 Question 92 Are human umbilical cord-derived mesenchymal stem cells (UC-MSCs) safe and effective 93 therapeutic option for limiting lung damage in severe coronavirus disease 2019 94 (COVID-19)? 95 Finding 96 In this randomised, double-blind, placebo-controlled, phase 2 trial that included 100 97 COVID-19 patients with lung damage, human UC-MSCs medication showed a trend of 98 improvement in whole lung lesion size and significantly reduced the proportions of 99 consolidation lesions from baseline to day 28 in the treated patients compared with the 100 placebo subjects. The 6-minute walk test showed a longer distance in UC-MSCs than 101 placebo group but without significantly difference. UC-MSCs delivery was well tolerated, 102 with no serious adverse events. 103 Meaning 104 Human UC-MSC administration for hospitalized COVID-19 with lung damage is safe. 105 Treatment with human UC-MSC improves the resolution of lung lesions, particularly the 106 consolidation lesions. 107 108 Page 6 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20213553; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 109 Introduction 110 The Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome 111 coronavirus 2 (SARS-CoV-2) infection,1 causes substantial damage to lungs, ranging from 112 mild respiratory illness to severe acute respiratory syndrome, and death,2-4 Dysregulated 113 immune responses of both the innate and adaptive immune systems are associated with 114 disease severity, lung damage and long term functional disability.5-8 There are currently no 115 prophylactic vaccines or effective antiviral agents available to treat COVID-19 and 116 management of COVID-19 patients remains largely symptomatic and supportive therapy.9 117 Therefore, there is an urgent need for safe and alternative therapeutic options to mitigate 118 inflammatory organ injury.
Load more

Recommended publications
  • Treatment with Convalescent Plasma for COVID‐19 Patients in Wuhan
    Tangfeng Lv ORCID iD: 0000-0001-7224-8468 Treatment with convalescent plasma for COVID-19 patients in Wuhan, China Mingxiang Ye, MD, PhD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Dian Fu, MD Department of Urology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Yi Ren, MD Department of Emergency, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.25882. Accepted Article This article is protected by copyright. All rights reserved. Faxiang Wang, MD Department of Emergency, 904 Hospital, Wuxi, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Dong Wang, MD, PhD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Fang Zhang, MD Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China Xinyi Xia, MD Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China Department of Laboratory Medicine, Wuhan Huoshenshan Hospital, Wuhan, China Accepted Article This article is protected by copyright.
    [Show full text]
  • Policy Disparities in Response to the First Wave of COVID-19 Between China and Germany Yuyao Zhang1, Leiyu Shi2, Haiqian Chen1, Xiaohan Wang1 and Gang Sun1,2*
    Zhang et al. International Journal for Equity in Health (2021) 20:86 https://doi.org/10.1186/s12939-021-01424-3 RESEARCH Open Access Policy disparities in response to the first wave of COVID-19 between China and Germany Yuyao Zhang1, Leiyu Shi2, Haiqian Chen1, Xiaohan Wang1 and Gang Sun1,2* Abstract Objective: Our research summarized policy disparities in response to the first wave of COVID-19 between China and Germany. We look forward to providing policy experience for other countries still in severe epidemics. Methods: We analyzed data provided by National Health Commission of the People’s Republic of China and Johns Hopkins University Coronavirus Resource Center for the period 10 January 2020 to 25 May 252,020. We used generalized linear model to evaluate the associations between the main control policies and the number of confirmed cases and the policy disparities in response to the first wave of COVID-19 between China and Germany. Results: The generalized linear models show that the following factors influence the cumulative number of confirmed cases in China: the Joint Prevention and Control Mechanism; locking down the worst-hit areas; the highest level response to public health emergencies; the expansion of medical insurance coverage to suspected patients; makeshift hospitals; residential closed management; counterpart assistance. The following factors influence the cumulative number of confirmed cases in Germany: the Novel Coronavirus Crisis Command; large gathering cancelled; real-time COVID-19 risk assessment; the medical emergency plan; schools closure; restrictions on the import of overseas epidemics; the no-contact protocol. Conclusions: There are two differences between China and Germany in non-pharmaceutical interventions: China adopted the blocking strategy, and Germany adopted the first mitigation and then blocking strategy; China’s goal is to eliminate the virus, and Germany’s goal is to protect high-risk groups to reduce losses.
    [Show full text]
  • CONNECTION the Official Newsletter of Zhejiang University Issue 16 Feb.2020
    CONNECTION The Official Newsletter of Zhejiang University Issue 16 Feb.2020 COVID-19 Special Issue Stand Strong Message from Editor-in-Chief CONNECTION Welcome to the special COVID-19 issue of Issue 16 CONNECTION, which highlights the efforts and contributions of ZJU community in face of the epidemic. As a group, they are heroes in harm's way, givers and doers who respond swiftly to the need of our city, our country and the world. When you read their stories, you'll recognize the strength and solidarity that define all ZJUers. ZJU community has demonstrated its courage and resilience in the battle against the novel coronavirus. At this time, let us all come together to protect ourselves and our loved ones, keep all those who are at the front lines in our prayers and pass on our gratitude to those who have joined and contributed to the fight against the virus. Together, we will weather this crisis. LI Min, Editor-in-Chief Director, Office of Global Engagement Editorial office : Global Communications Office of Global Engagement, Zhejiang University 866 Yuhangtang Road, Hangzhou, P.R. China 310058 Phone: +86 571 88981259 Fax: +86 571 87951315 Email: [email protected] Edited by : CHEN Weiying, AI Ni Designed by : HUANG Zhaoyi Material from Connection may be reproduced accompanied with appropriate acknowledgement. CONTENTS Faculty One of the heroes in harm’s way: LI Lanjuan 03 ZJU medics answered the call from Wuhan 04 Insights from ZJU experts 05 Alumni Fund for Prevention and Control of Viral Infectious Diseases set up 10 Alumni community mobilized in the battle against COVID-19 11 Education Classes start online during the epidemic 15 What ZJUers feel about online learning 15 Efforts to address concerns, avoid misinformation 17 International World standing with us 18 International students lending a hand against the epidemic 20 What our fans say 21 FacultyFaculty ZJU community has taken on the responsibility to join the concertedZJU community efforts has takenagainst on thethe responsibility spreadto join the of concerted the virus.
    [Show full text]
  • Emergency Architecture. Modular Construction of Healthcare Facilities As a Response to Pandemic Outbreak
    E3S Web of Conferences 274, 01013 (2021) https://doi.org/10.1051/e3sconf/202127401013 STCCE – 2021 Emergency architecture. Modular construction of healthcare facilities as a response to pandemic outbreak Marina Smolova1, and Daria Smolova2[0000-0002-2297-0505] 1Kazan State University of Architecture and Engineering, 420043 Kazan, Russia 2NFOE Inc., QC H2Y 2W7 Montreal, Canada Abstract. Emerging infectious diseases originating from wildlife species continue to demolish humankind leaving an imprint on human history. December 2019 has marked the emergence of a novel coronavirus named SARS-CoV-2 (Covid-2019) originated in China in the city of Wuhan. Drastic emergence and spread of infectious disease have shown to appear in highly densified areas causing rapid spread of epidemic through population movement, transmission routes, major activity nodes, proximity, and connectivity of urban spaces. An extreme number of cases rising throughout the world caused space unavailability in healthcare facilities to serve patients infected with Covid-2019, therefore urging for innovative emergency management response from construction and architecture industry. Prefabricated modular construction has been widely utilized around the globe assembling rapid response facilities after catastrophic events such as tornadoes, hurricanes, and forest fires. An increasing number of Covid-2019 cases demanded effective and compressed implementation of medical centres to provide expeditious and secure healthcare. The paper examines the potential of standardization of modular construction of hospitals as a response to current and potential pandemic outbreaks. The research provides fundamental planning requirements of isolation units and their design flexibility as a key to rapid emergency solution. Keywords. Modular construction, prefabrication, prefabricated construction, emergency architecture, healthcare facilities, hospitals, prefabricated architecture, Covid-2019.
    [Show full text]
  • Clinical Course and Risk Factors for In-Hospital Death in Critical COVID-19 in Wuhan, China
    medRxiv preprint doi: https://doi.org/10.1101/2020.09.26.20189522; this version posted September 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Clinical Course And Risk Factors For In-hospital Death In Critical COVID-19 In Wuhan, China Fei Li, MD, PhD1,2#, Yue Cai, MD1,2#, Chao Gao, MD, PhD1#, Lei Zhou, MD, PhD2,3#, Renjuan Chen, MD, PhD1, Kan Zhang, MD1,2, Weiqin Li, MD2,4, Ruining Zhang, MD1, Xijing Zhang, MD, PhD2,5, Duolao Wang, PhD 6*, Yi Liu, MD, PhD1*, Ling Tao, MD, PhD1* 1. Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China 2. Huoshenshan Hospital, Wuhan, China 3. Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi’an, China 4. Department of Critical Care Medicine, Jinling Hospital, Nanjing, China 5. Surgical ICU, Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China 6. Department of Clinical Sciences Liverpool School of Tropical Medicine Pembroke, Liverpool, United Kingdom Address for correspondence: Professor Ling Tao, MD, PhD. Professor of Cardiology – Xijing hospital, Xi’an, China 127 Changle west road, Xi’an, 710032, China Email: [email protected] Professor Yi Liu, MD, PhD. Professor of Cardiology – Xijing hospital, Xi’an, China 127 Changle west road, Xi’an, 710032, China Email: liuyimeishan@hotmail,.com 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • A Crisis Like No Other
    Rose LeMay Susan Riley Dayna Mahannah Jatin Nathwani Gwynne Dyer Why we need Parliamentary The uncertainty embedded COVID-19 crisis Toddler in chief in the race-based data on accountability or pandemic in oil and gas serves up off ers hope for a clean White House is frantic to COVID-19 p. 5 pandemonium? p. 4 another option p. 20 energy transition p. 18 reopen the economy p. 15 Michael Harris p.11 THIRTY-FIRST YEAR, NO. 1720 CANADA’S POLITICS AND GOVERNMENT NEWSPAPER MONDAY, APRIL 20, 2020 $5.00 News Canada-U.S.News COVID-19 & leadership News Senate Trump coronavirus Senate’s new pronouncements Next federal election a have had little COVID-19 impact on Canadian oversight response as few referendum on Trudeau’s committees have been realized, should leave say analysts management of rough stuff for BY NEIL MOSS the House, say s U.S. President Donald COVID-19, say pollsters, ATrump makes headline- grabbing suggestions that could Senators have wide-reaching effects on Canada’s response to curb CO- ‘a crisis like no other’ BY PETER MAZEREEUW VID-19, analysts say the presiden- tial pronouncements have little wo Senate committees just Veteran pollster Frank Graves says the COVID-19 global pandemic has brought the Tassigned to monitor the gov- Continued on page 23 world to the ‘cusp of another great transformation,’ but it’s unknown what changes it ernment’s response to COVID-19 should leave partisanship at the will create until this international crisis is over. But it’s never going back to normal. door, and cut the government some slack as it
    [Show full text]
  • COVID-19 Containment: China Provides Important Lessons for Global Response
    Front. Med. https://doi.org/10.1007/s11684-020-0766-9 COMMENTARY COVID-19 containment: China provides important lessons for global response * Shuxian Zhang1,*, Zezhou Wang2, , Ruijie Chang1, Huwen Wang1, Chen Xu1, Xiaoyue Yu1, Lhakpa Tsamlag1, Yinqiao Dong3, Hui Wang (✉)1, Yong Cai (✉)1 1School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2Department of Cancer Prevention, Shanghai Cancer Center, Fudan University, Shanghai 200032, China; 3Department of Environmental and Occupational Health, School of Public Health, China Medical University, Shenyang 110122, China © Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020 Abstract The world must act fast to contain wider international spread of the epidemic of COVID-19 now. The unprecedented public health efforts in China have contained the spread of this new virus. Measures taken in China are currently proven to reduce human-to-human transmission successfully. We summarized the effective intervention and prevention measures in the fields of public health response, clinical management, and research development in China, which may provide vital lessons for the global response. It is really important to take collaborative actions now to save more lives from the pandemic of COVID-19. Keywords coronavirus disease 2019 (COVID-19); control measure; public health response Background “very high” at a global level. China’s approach to contain the spread of the virus has changed the trajectory of the The novel coronavirus disease (COVID-19) is now fast epidemic [3]. China’s efforts to contain the novel spreading to 94 countries and, updated as of March 7, coronavirus can provide vital lessons for other nations 2020, 101 927 confirmed cases have been reported experiencing the rapid spreading or at the risk of an worldwide [1].
    [Show full text]
  • Sex-Based Clinical and Immunological Differences in COVID-19
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.29.20126201; this version posted September 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Sex-based clinical and immunological differences in COVID-19 Kening Li1,2,3†; Bin Huang2,3†; Yun Cai2,3†; Zhihua Wang4,5†; Lu Li2,3; Lingxiang Wu2,3; Mengyan Zhu2,3; Jie Li2,3; Ziyu Wang2,3; Min Wu2,3; Wanlin Li2,3; Wei Wu2,3; Lishen Zhang2,3; Xinyi Xia1,5,6*; Shukui Wang7*; Qianghu Wang2,3,8* 1COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, China 2Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China 3Department of Bioinformatics, Nanjing Medical University, Nanjing, Jiangsu 211166, China 4Department of Laboratory Medicine & Blood Transfusion, the 907th Hospital, Nanping, Fujian 350702, China 5Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan 430100, China 6Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, Hubei 430100, China 7Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China 8State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 211166, China. †Kening Li, Bin Huang, Yun Cai, and Zhihua Wang contributed equally to this article Correspondence to: Xinyi Xia, [email protected]; Shukui Wang, [email protected]; Qianghu Wang, [email protected].
    [Show full text]
  • February 2020 ` 50 News from China China-India Review
    Vol. XXXII | No.2 | February 2020 ` 50 NEWS FROM CHINA CHINA-INDIA REVIEW PEOPle’s WAR CHINA SHALL OVERCOME PEOPLE POWER MARCHING TOGETHER H.E. SUN WEIDONG From Ambassador’s Desk China’s Ambassador to India China Unites to Win People’s War nation’s strength is tested in difficult of the Political Bureau and decided to set up times. The Chinese leadership and the Central Leading Group on Responding to Apeople have united and joined hands to COVID-19 Outbreak. It has never happened defeat the deadly COVID-19 (novel coronavirus before in Chinese history to have this highest- pneumonia) epidemic. The Chinese government level meeting on the first day of the Spring has taken the most comprehensive, rigorous Festival. It demonstrated that for President Xi and thorough prevention and control measures. curbing the epidemic is foremost priority and We have been working literally 24x7 to win this he is ready to leave no stone unturned in this “People’s War,” as President Xi has said. mission. The results of these cumulative efforts show In this battle against the epidemic, we are a new dawn breaking through darkness. The reassured by growing international support recovery rate of COVID-19 patients in Hubei and solidarity with China. In this context, I will Province surged from 7.14% on Feb. 12 to 53.81% like to thank Prime Minister Narendra Modi on March 2. There is a sharp drop in the fatality for writing a letter to President Xi, expressing rate, with 3,728 patients in severe and critical India’s solidarity with China.
    [Show full text]
  • China Economic Monitor: Q1 2020
    China Economic Monitor Q1 2020 KPMG China April 2020 kpmg.com/cn Contents Executive summary 2 1 Economic trends 5 ❑ Outbreak of COVID-19 pandemic 6 ❑ Economic impact of COVID-19 will be far worse than SARS 9 ❑ Strengthening regulation through policies to minimise economic impacts 14 ❑ Impacts of COVID-19 on the global economy 17 ❑ New economy accelerated by COVID-19 20 ❑ China’s economy in Q4 and full year 2019 21 ❑ Column: Phase 1 trade deal signed by the US and China 25 2 ❑ Policy analysis 28 ❑ Securities Law amendments and full implementation of the registration system 29 ❑ Release of the “28 Measures” supporting private enterprises 33 ❑ Significant relaxation of urban settlement policies 38 ❑ Important adjustments to China’s regional development policies 41 ❑ The Foreign Investment Law and its implementation regulations officially take effect 45 3 ❑ Special study: China’s Social Credit System construction and its implications 47 ❑ China accelerates Social Credit System construction 48 ❑ Four pillars of China’s Social Credit System 49 ❑ China’s Social Credit System: framework and features 50 ❑ How should companies address the opportunities and challenges of the Social Credit System 55 Appendix: Key indicators 58 Executive summary China’s economy and society have been significantly impacted by the outbreak of 2019 Novel Coronavirus As China heads towards the last year of the 13th Five- Infected Pneumonia (COVID-19) since early 2020. Year Plan and strives to achieve a moderately Although the macro-economy of China barely slowed prosperous society in all respects, “keeping moderate down during the SARS outbreak (in fact, annual GDP economic growth” remains a top priority in policy- growth in 2003 was even higher than in 2002), the making.
    [Show full text]
  • The Physical and Mental Health for the Medical Staff Caring for Patients with COVID-19 in Wuhan Huoshenshan Hospital: a Structural Equation Modeling
    The physical and mental health for the medical staff caring for patients with COVID-19 in Wuhan Huoshenshan Hospital: A structural equation modeling Jinyao Wang Sichuan University West China Hospital Dan-Hong Li Xinqiao Hospital Xiu-Mei Bai Xinqiao Hospital Jun Cui West China Hospital Lu Yang Sichuan University West China Hospital Xin Mu Sichuan University West China Hospital Rong Yang ( [email protected] ) Sichuan University West China Hospital https://orcid.org/0000-0002-9044-331X Research Keywords: COVID-19, Wuhan Huoshenshan Hospital, medical staff, Fatigue, Anxiety, Resilience, SEM Posted Date: August 18th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-58110/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Background: Early in the epidemic of corona virus disease 2019 (COVID-19), Chinese government had recruited a portion of military healthcare workers to support the designated hospital (Wuhan Huoshenshan Hospital) to relieve the front-line workload in Wuhan, China. It was reported that the majority of the front-line medical staff (FLMS) suffered from adverse effects, but their physical and psychological health status and its relationship were still unknown. Hence, a structural equation modeling (SEM) was conducted to establish and test the latent relationship among variables. Methods: This is a cross-sectional study. Totally 115 convenience samples of military medical staff from Xinqiao Hospital in Chongqing were enrolled during February 17th to February 29th, 2020. The medical staff assisting in Huoshenshan Hospital were selected as experimental group(n=55), the other medical staff were control group(n=60).
    [Show full text]
  • Respond to the COVID-19 Pandemic: Strategies Comparison in Six Countries
    Respond to the COVID-19 pandemic: strategies comparison in six countries Haiqian Chen Southern Medical University Leiyu Shi Southern Medical University Yuyao Zhang Southern Medical University Xiaohan Wang Southern Medical University Jun Jiao Southern Medical University Manfei Yang Southern Medical University Gang Sun ( [email protected] ) Johns Hopkins University https://orcid.org/0000-0002-9642-2886 Research Keywords: COVID-19, containment strategy, mitigation strategy, countries comparison Posted Date: May 4th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-455879/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/22 Abstract Objective This study aimed to examine the effectiveness of the containment strategy and mitigation strategy taken by six countries. Methods We extracted publicly available data from various ocial websites, summarized the strategies implemented in these six countries, and assessed the effectiveness of the prevention and control measures adopted by these countries. Results Responding to an unprecedented COVID-19 pandemic, China, South Korea, and Singapore adopted containment strategies, and China and Singapore had a similar epidemic curve and the new daily cases. As of December 31, 2020, the new daily cases of China and Singapore were below less than 100 with the mortality rates per 100,000 population 0.3% and 0.5% respectively. But the new daily cases of South Korea as high as 1029 with the mortality rates per 100,000 1.8%. In contrast, the United States, the United Kingdom, and France responded with mitigation strategies, and had similar epidemic curves and mortality rates per 100,000 population.
    [Show full text]